计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| L414153-1mg |
1mg |
现货 ![]() |
| |
| L414153-5mg |
5mg |
期货 ![]() |
| |
| L414153-10mg |
10mg |
现货 ![]() |
| |
| L414153-25mg |
25mg |
期货 ![]() |
| |
| L414153-50mg |
50mg |
现货 ![]() |
| |
| L414153-100mg |
100mg |
现货 ![]() |
|
| 别名 | 莱尼奥利西布 (CDZ 173) |
|---|---|
| 英文别名 | Q27282602 | US8653092, 67 | Example 67 [WO2012004299] | Leniolisib | Leniolisib; CDZ173 | DC22326 | GTPL9424 | Leniolisib (USAN/INN) | LENIOLISIB [WHO-DD] | s8752 | (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]p |
| 规格或纯度 | Moligand™, ≥99% |
| 英文名称 | leniolisib (CDZ 173) |
| 生化机理 | 莱尼利西布(CDZ 173)是一种强效的 PI3Kδ 选择性抑制剂,对 PI3Kα、PI3Kβ、PI3Kγ 和 PI3Kδ 的生化 IC50 值分别为 0.244、0.424、2.23 和 0.011 μM。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | PI3 激酶 p110-delta 亚基抑制剂 |
| 产品介绍 |
Information Leniolisib (CDZ 173) is a potentPI3Kδselective inhibitor withbiochemical IC50 valuesof 0.244, 0.424, 2.23 and 0.011 μM for PI3Kα, PI3Kβ, PI3Kγ and PI3Kδ, respectively. Targets PI3Kδ (Cell-free assay); PI3Kα (Cell-free assay); PI3Kβ (Cell-free assay); DNA-PK ; DNA-PK (Cell-free assay) 31052,0.011 μM; 0.244 μM; 0.424 In vitro CDZ173 inhibits a large spectrum of immune cell functions, as demonstrated in B and T cells, neutrophils, monocytes, basophils, plasmocytoid dendritic cells, and mast cells. CDZ173 showed no activity up to the highest test concentration when tested against CYP isoform assays (3A3, 2D9, 2D6, 2C9), a panel of ion channels (including hERG) and a protease panel. In a panel of 50 safety related targets (GPCRs, ion channels, transporters), CDZ173 only showed measurable activity for hPDE4D (IC50 = 4.7 μM) and 5HT2B (IC50 = 7.7 μM). In vivo CDZ173 inhibits B cell activation in rats and monkeys in a concentration- and time-dependent manner. After prophylactic or therapeutic dosing, CDZ173 potently inhibited antigen-specific antibody production and reduced disease symptoms in a rat collagen-induced arthritis model. CDZ173 is absorbed very quickly across species as can be seen by an early Tmax of the oral profiles. Whereas clearance is low to moderate in rats and monkeys, it was found that clearance in dogs is very low resulting in a very high exposure in blood. Plasma protein binding in dogs is very high (>99%) and the distribution of the compound is restricted into tissue (Vss = 0.3 L/kg). |
| 纯度 | ≥99% |
| IC50 | PI3Kδ, IC50: 0.011 μM |
|---|---|
| ALogP | 2.65 |
| hba_count | 5 |
| HBD Count | 1 |
| Rotatable Bond | 6 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 504771611 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one |
| INCHI | 1S/C21H25F3N6O2/c1-3-18(31)30-6-4-13(10-30)28-19-15-11-29(7-5-17(15)26-12-27-19)14-8-16(21(22,23)24)20(32-2)25-9-14/h8-9,12-13H,3-7,10-11H2,1-2H3,(H,26,27,28)/t13-/m0/s1 |
| InChi Key | MWKYMZXCGYXLPL-ZDUSSCGKSA-N |
| Smiles | CCC(=O)N1CCC(C1)NC2=NC=NC3=C2CN(CC3)C4=CC(=C(N=C4)OC)C(F)(F)F |
| Isomeric SMILES | CCC(=O)N1CC[C@@H](C1)NC2=NC=NC3=C2CN(CC3)C4=CC(=C(N=C4)OC)C(F)(F)F |
| 分子量 | 450.46 |
| Reaxy-Rn | 26178216 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=26178216&ln= |
| 溶解性 | Solubility (25°C) In vitro DMSO: 90 mg/mL (199.79 mM); Ethanol: 13 mg/mL (28.85 mM); Water: Insoluble; |
|---|---|
| DMSO(mg / mL) Max Solubility | 90 |
| DMSO(mM) Max Solubility | 199.795764329796 |
| Water(mg / mL) Max Solubility | <1 |
| 分子量 | 450.500 g/mol |
| XLogP3 | 2.500 |
| 氢键供体数Hydrogen Bond Donor Count | 1 |
| 氢键受体数Hydrogen Bond Acceptor Count | 10 |
| 可旋转键计数Rotatable Bond Count | 5 |
| 精确质量Exact Mass | 450.199 Da |
| 单同位素质量Monoisotopic Mass | 450.199 Da |
| 拓扑极表面积Topological Polar Surface Area | 83.500 Ų |
| 重原子数Heavy Atom Count | 32 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 654.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 1 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 1. Lucas CL, Kuehn HS, Zhao F, Niemela JE, Deenick EK, Palendira U, Avery DT, Moens L, Cannons JL, Biancalana M et al.. (2014) Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency.. Nat Immunol, 15 (1): (88-97). [PMID:24165795] |
| 2. Wentink M, Dalm V, Lankester AC, van Schouwenburg PA, Schölvinck L, Kalina T, Zachova R, Sediva A, Lambeck A, Pico-Knijnenburg I et al.. (2017) Genetic defects in PI3Kδ affect B-cell differentiation and maturation leading to hypogammaglobulineamia and recurrent infections.. Clin Immunol, 176 (77-86). [PMID:28104464] |
| 3. Hoegenauer K, Soldermann N, Zécri F, Strang RS, Graveleau N, Wolf RM, Cooke NG, Smith AB, Hollingworth GJ, Blanz J et al.. (2017) Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors.. ACS Med Chem Lett, 8 (9): (975-980). [PMID:28947947] |
| 4. Rao VK, Webster S, Dalm VASH, Šedivá A, van Hagen PM, Holland S, Rosenzweig SD, Christ AD, Sloth B, Cabanski M et al.. (2017) Effective "activated PI3Kδ syndrome"-targeted therapy with the PI3Kδ inhibitor leniolisib.. Blood, 130 (21): (2307-2316). [PMID:28972011] |